Types of treatments used as prior lines before study entry
| Type of treatments used as prior lines before study entry, n (%) . | First line (n = 403) . | Second line (n = 183) . | Third line (n = 85) . | Later lines (n = 75) . |
|---|---|---|---|---|
| Anthracycline based | 222 (55.1) | 34 (18.6) | 12 (14.1) | 8 (10.7) |
| Alkylator based | 134 (33.3) | 40 (21.9) | 21 (24.7) | 28 (37.3) |
| Bendamustine | 23 | 15 | 7 | 5 |
| Fludarabine based | 12 (3.0) | 18 (9.8) | 7 (8.2) | 8 (10.7) |
| Anti-CD20 monotherapy | 11 (2.7) | 34 (18.6) | 16 (18.8) | 16 (21.3) |
| Standard salvage∗ | 1 (0.2) | 28 (15.3) | 8 (9.4) | 8 (10.7) |
| Other | 19 (4.7) | 29 (15.8) | 21 (24.7) | 7 (9.3) |
| Type of treatments used as prior lines before study entry, n (%) . | First line (n = 403) . | Second line (n = 183) . | Third line (n = 85) . | Later lines (n = 75) . |
|---|---|---|---|---|
| Anthracycline based | 222 (55.1) | 34 (18.6) | 12 (14.1) | 8 (10.7) |
| Alkylator based | 134 (33.3) | 40 (21.9) | 21 (24.7) | 28 (37.3) |
| Bendamustine | 23 | 15 | 7 | 5 |
| Fludarabine based | 12 (3.0) | 18 (9.8) | 7 (8.2) | 8 (10.7) |
| Anti-CD20 monotherapy | 11 (2.7) | 34 (18.6) | 16 (18.8) | 16 (21.3) |
| Standard salvage∗ | 1 (0.2) | 28 (15.3) | 8 (9.4) | 8 (10.7) |
| Other | 19 (4.7) | 29 (15.8) | 21 (24.7) | 7 (9.3) |
Prior maintenance rituximab (any line) was administered to 164 (40%) patients; prior high-dose chemotherapy + autologous stem cell transplant (any line) was administered to 23 (5.7%) patients.
Salvage therapy includes ifosphamide, carboplatin, etoposide; dexamethasone, cytarabine, cisplatin; and etoposide, cisplatin, cytarabine, prednisone; with or without rituximab.